This study presents the characterization of an experimental immunotherapeutic approach for schistosomiasis utilizing antiidiotypic antibodies. Antiidiotype (31-3B6) was generated in rabbits using a protective murine monoclonal antibody 31-3B6 which recognizes a 68,000-D molecular mass glycoprotein present in extracts of Schistosomiasis mansoni adult worm homogenetics. Immunization of mice with antiidiotype (31-3B6) before S. mansoni cercariae infection resulted in protection levels ranging from 16 to 41% depending on the route of administration of antiidiotypic antibody and the use of adjuvant. Levels of protection as high as 25% could be obtained with a single injection of antiidiotype (31-3B6) without the use of adjuvant. Animals noted to be resistant to infection with S. mansoni cercariae were also noted to exhibit a humoral immune response that bound components of S. mansoni adult worm homogenetics. This induced antiantigen immune response was shown to bind to the surface of S. mansoni schistosoma by indirect immunofluorescence. Further characterization of the induced antiantigen response showed that a portion (3-32%) of the induced humoral immune response portrayed the binding specificities of the murine monoclonal antibody 31-3B6. The data indicate that antiidiotype antibodies generated utilizing defined monoclonal antibodies can act as surrogate antigens in the protection of infection in schistosomiasis.
Introduction
The immune response to a given antigen can be regulated through a series of complementary interactions involving idiotypic and antiidiotypic determinants (1) . Numerous studies have shown that idiotype-antiidiotype interactions can result in either suppression or stimulation of an immune response (2) (3) (4) . When antigen is presented to the immune system, immunoglobulin reactive to antigen is produced (Ab1). These antibody molecules have unique structural components, termed idiotypes, which can stimulate a second cascade of antibodies (Ab2) directed at these unique structures. These anti-antiantigen molecules are termed antiidiotypic antibodies. The regulation of immune responses by these molecules is based on the complementary structural relationship between idiotype and antiidiotype, particularly when the relevant idio-type is in or near the antigen binding site. Specifically, antiidiotypic antibodies that are antigen binding site-related often portray the internal image of antigen (5) (6) (7) . These internal image antiidiotypic antibodies stimulate the immune system in a similar fashion to antigen by mimicking its antigenic structure. In this capacity, antiidiotypic antibody, which portrays the internal image of antigen, can induce an immune response (Ab3) that is anti-antigen. In effect, antiidiotypic antibodies (Ab2) stimulate an Ab3 response that is serologically and functionally identical to the Ab1 response induced by antigen.
Application of these observations has resulted in antiidiotype antibody vaccine(s) against a variety of infectious pathogens and tumors in several species of experimental animals including primates (8) (9) (10) (11) (12) (13) . The initial report of an effective antiidiotype vaccine involved the induction of protective immunity against the protozoa, Trypansoma rhodesiense infection ( 1 4, 15) . With other infectious diseases including Streptococcus pneumonia (16), Escherichia coli K13 infections (17) , hepatitis B virus (18), Sendai virus (19) , reovirus (20) , and polio virus type III (21) the principle of idiotypic vaccination has been applied. In these studies varying levels of protective immunity were induced. In the present investigation an antiidiotypic antibody vaccine was developed against the multicellular helminth, Schistosoma mansoni and shown to induce protection against a primary challenge by infective cercariae using various vaccination protocols. Protection was noted even when the antiidiotypic antibody vaccine was given without adjuvant or after a single administration. When directly compared to purified antigen, equal or lower concentrations of antiidiotype induced equivalent in vivo protection. Analysis of the antischistosomal immune response, induced by the antiidiotype vaccine, indicated that vaccination resulted in an antibody response directed toward a defined antigen as well as the surface of schistosoma (the invasive larval form of the parasite). Taken together, these data indicate that antiidiotype vaccines in schistosomiasis induce effective protection to reinfection by acting as structural surrogates of protective antigens. Methods 31-3B6 is an IgM monoclonal antibody produced from the fusion of splenocytes of a Balb/C mouse hyperimmunized with adult schistosome antigens (SWAP) with the Balb/C myeloma line P3NSl (22) .
Supernatants from the resultant hybrid clones were screened for reactivity with SWAP by ELISA and binding to living schistosomula by indirect immunofluorescence and shown to be a candidate vaccine (22) . Large quantities of monoclonal antibodies were produced in Balb/C mice as ascites fluid.
For the present studies, 31-3B6 antibody was purified from ascites fluid by ammonium sulfate precipitation and molecular sieve chromatography using a CL6B column (Pharmacia Fine Chemicals, Piscata-Xenogeneic antiidiotypic antisera was generated in the following manner. 5 mg of chromatographically purified 31-3B6 antibody was emulsified in complete Freund's adjuvant and injected subcutaneously into numerous spots on the back, axilla, and groin ofthree 3-5-kg New Zealand white rabbits.
Immunization was repeated 2 wk later with purified 31-3B6 antibody and incomplete Freund's adjuvant. All rabbits were then boosted with 3 l-3B6 antibody (5 mg/rabbit) subcutaneously every other week for a total of eight doses. 1 wk after the last immunization, animals were bled via an ear artery and serum was collected. Balb/C immunoglobulin was prepared from ascites fluid of pristane-treated mice by a 33% ammonium sulfate precipitation. All three rabbit sera produced a dense precipitation band with purified 31-3B6 as well as purified Balb/C immunoglobulin by Ouchterlony analysis.
Purified Balb/C immunoglobulin was covalently coupled to Sepharose. Mouse antiisotypic and antiallotypic antibodies present in these rabbit sera were then absorbed by chromatography. Reactivity for 31-3B6 antibody versus normal mouse IgM was determined by Ouchterlony analysis and subsequently by an assay for idiotype reactivity (23, 24) as described below. Only one rabbit produced an absorbed anti-sera that precipitated on Ouchterlony analysis as a dense band with 31-3B6 antibody but not with Balb/C immunoglobulin. This rabbit was repeatedly boosted and bled and various serum pools created. One pool of 200 cm3 of serum was absorbed, tested, and used for the experiments outlined.
Quantification ofanti-id activity. Rabbit antiidiotype activity was quantified by an indirect method of precipitation as described previously (23, 24) . In brief, purified 31-3B6 was labeled with 125I using chloramine T (25). 10 ng ofthis labeled ligand was then incubated with serial dilutions (1:10 to 1:20,480) of absorbed rabbit antisera. This reaction mixture also contains 10 (23, 24) and ELISA were used to determine the characteristic binding patterns of rabbit anti-idiotype 31-3B6. ELISA was performed as described previously (22) (27) .
Resistance to infection was determined by either recovery of migrating larvae from the lungs (28) or recovery of adult worms from the mesenteric vasculature ofinfected mice (27) . In the former assay, mice were anesthesized and infected with 500 cercariae. Animals were killed 7 d later, their lungs were removed, and the number ofmigrating larvae were enumerated microscopically (28) . Adult worm recoveries were performed in animals infected with 100 cercariae 6 wk postinfection (27) . Anesthesized mice have their portal systems perfused and the number of adult worms/mouse enumerated.
To determine percent protection the following formula was used: Worms recovered from control mice -Worms recovered from X 100 experimental mice/Worms recovered from control mice. Statistical analysis of data was performed using the Student's t test.
Antibody response ofvaccinated animals. Serum from control animals or mice vaccinated with antiidiotypic antibody was examined for its ability to bind soluble worm antigens (SWAP) by ELISA as previously described (29) . In brief, SWAP is produced from adult S. mansoni worms by emulsification with a tissue grinder and ultracentrifugation (30 A second assay performed to determine the specificity of induced Ab3 antibody in vaccinated mice utilized the purified 68-kD antigen as a competitive inhibitor. The 68-kD antigen, recognized by monoclonal antibody 31-3B6 was used to inhibit the binding of induced Ab3 to antigen (SWAP). Therefore, this RIA would substantiate the initial observation that Ab3 antibodies induced by vaccination with antiidiotypic antibody (Ab3) could recognize a specific SWAP antigen related to the molecule used to induce the Ab3 population. In these studies increasing amounts of 68 kD antigen (10-5,000 ng) were preincubated with murine antisera at 37°C for I h before incubation in SWAPcoated polyvinyl microtiter plates. Binding was detected using a 12511 goat anti-mouse IgG. Data is presented as percent inhibition ofbinding to antigen by nanogram quantities of 68 kD antigen.
Results
Antiidiotypic binding of rabbit serum. Serum from outbred rabbits hyperimmunized with monoclonal antibody 31-3B6 was absorbed by passage through normal mouse immunoglobulin coupled-Sepharose columns. Absorbed sera that was negative for binding to normal mouse immunoglobulin but which precipitated 31-3B6 antibody was then analyzed quantitatively for binding to radiolabeled ligand (31-3B6) in an assay for idiotype. As shown in Fig. 1 antiidiotype antibody containing absorbed rabbit sera bound > 80% of radiolabeled 31-3B6 monoclonal antibody in the presence of a two-log excess of normal mouse immunoglobulin. These data indicate that the absorbed rabbit sera recognized epitopes specific to variable regions found on monoclonal antibody 31-3B6. Background binding levels in this assay, using either BSA or an irrelevant monoclonal antibody, were < 5% ofthe labeled ligand. Analysis of the binding curve also demonstrated that 500 ,ug of absorbed rabbit serum contained 750 ng idiotype binding capacity (IBC) of activity.
Antiidiotypic antibody as a vaccine in S. mansoni. In initial studies, anti-idiotypic antibody was used to hyperimmunize CF1 outbred mice. As shown in Table I , mice hyperimmunized with rabbit anti-id (31-3B6) showed a 41% reduction in migrating larvae recovered from the lung when compared to mice hyperimmunized with rabbit serum (P < 0.001). Lung recoveries of migrating larvae was used as an initial screen since this assay has been shown to have a good correlation with adult worm recovery and can be performed in far shorter time intervals. The results of these initial studies were confirmed by measuring adult worms recovered from the mesenteric vasculature 6 wk postinfection in additional studies utilizing identical treatment protocols. As shown in Table I , a level of 43% protection was noted.
Protection from S. mansoni infection varies with immunization protocol. The previous observation noted that mice hyperimmunized with antiidiotype (31-3B6) were resistant to primary infection with S. mansoni cercariae. Subsequent studies used varying immunization protocols, with and without adjuvant, with resistance to infection assessed by lung recoveries. Further studies identifying the binding characteristics of polyclonal antiidiotype 31-3B6 are presented in Table VI . These data show that all animals protected from S. mansoni infection by antiidiotypic administration portray binding activity to absorbed polyclonal rabbit antiidiotype as determined (id-anti-id immune network) was investigated in the rat model of S. mansoni infection (36, 37) . In this animal model of schistosomiasis, the Fisher rat strain developed resistance to reinfection following exposure to low numbers of cercariae (comparable to the level of infection in the present study). Table I ). * Sample, Animal number of mice administered polyclonal antiidiotypic antibody (see Table I ). § Serum bleed 5 d after injection of antiidiotypic antibodies.
Therefore, serum from Fisher rats twice infected with S. mansoni cercariae and portraying a 50-60% level of protection to reinfection, were utilized as inhibitors of 31-3B6-anti-idiotype binding. As shown in Table VII , a maximum level of inhibition (86%) of rabbit antiidiotype binding to 31-3B6 was noted with neat rat serum. This inhibition of binding by protective rat serum was titerable and evident even in the 1:1,000 dilution of serum tested. These data strongly indicate that rabbit polyclonal antiidiotype 31-3B6 contains Ab2fl based on the expression of 31-3B6 idiotypic repertoire in both rat and mouse models of S. mansoni infection.
Comparative protection induced bypurified 31-3B6 antigen versus anti-id (31-3B6) immunization. Previous studies (22) have shown that a defined 68,000-D glycoprotein parasite antigen identified by 31-3B6 induces anti-schistosomal protection in naive mice without the use of adjuvants. In the following experiments, antiidiotypic antibody (31-3B6) was directly (56) . The requirements of the induction of a protective antiidiotype-induced immune response to murine reovirus infection have been reported (57) . High titer of neutralizing antibody was noted using a chronic immunization protocol that utilized a regimen of complete and incomplete Freund's adjuvant or alum. An additional requirement was the cross-linking or covalent coupling of monoclonal antiidiotypic antibody to a carrier molecule (57) . These stringent requirements were not necessary, however, to produce anti-viral T cell immunity in mice (26) . In addition, as recently reviewed by Hiernaux (58), numerous experimental systems of infectious diseases have utilized antiidiotypic antibody without the use of adjuvant to induce protective immunity. As in the presently reported study, these volumes ofdata infer that various forms ofimmunity to infectious agents can be generated by using antiidiotype antibodies. However, the requirements for the type of protective immunity generated and level ofprotection depend on the individual experimental system.
In the present study, xenogeneic antiidiotypic antibody was used to induce varying levels of protection to a challenge with S. mansoni cercariae in outbred mice. Levels of protection ranged from 16 to 41% depending on the immunization protocol. Antiidiotype, however, remained effective even when given-as a single intravenous, subcutaneous, or intraperitoneal injection without adjuvant. Although this degree of resistance (16-43%) is modest compared to vaccines for other infectious diseases, it is important to note that helminths do not multiply in the definitive host and, therefore, anti-worm vaccines can have a significant impact on disease even if only partially effective (59) .
This level of resistance compares favorably to that observed in mice after the passive transfer of serum from S. mansoni infected animals (46), following adjuvant therapy (60) , following immunization with irradiated cercariae vaccines (39) (40) (41) , or immunization with purified antigens generally administered with complete Freund's or other adjuvant (61, 62 This antigen's mimicry quality of certain antiidiotypes has been suggested as the basis for other protective antiidiotype vaccines (8) . Mimicry was not, however, perfect in that antiidiotype vaccination resulted in Ab3 molecules that bound worm antigens but were not inhibited by either 31-3B6 or the 68-kD antigen. However, the present study, which does not detail the fine specificity of the Ab3 population, does not rule out the possibility of antibody affinity differences and cross-reactivity among the various antibody substrates. Nevertheless, the present observations raise the possibility that antiidiotype immunization may stimulate the production ofa broader immune response than purified antigen itself. The potential role of these Ab3 immunoglobulins, which may not strictly involve the 68-kD-3 1-3B6 immune network in the induction of resistance to Schistosoma mansoni, is presently under investigation.
Conclusion. An antiidiotype-based vaccine is a viable alternative to purified antigen-based vaccines or recombinant subunit vaccines particularly if the protective epitopes are carbohydrate in nature. Antiidiotype vaccines are effective in experimental schistosomiasis when given without adjuvants and even after a single immunization. Antiidiotype administration induced an Ab3 response that identifies the epitope-containing molecule which initiates the immune network and suggests that at least part of the mechanism of induced resistance by antiidiotype is through its molecular mimicry of antigen.
